A Prospective Study Investigating Predictability and Discrepancies in Initial Tacrolimus Dosing Using Genetic Information.

A Prospective Study Characterizing Patterns of Discrepancies Between Predicted and Observed Initial Tacrolimus Dosing in a CYP3A5 Genotype-Based Model. - TAC-PRED Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061408

Enrollment

Registered

2026-05-01

Start date

2026-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppressive therapy (tacrolimus dosing) in kidney transplant recipients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing kidney transplantation who initiate tacrolimus-based immunosuppressive therapy and provide informed consent for participation.

Exclusion criteria

Exclusion criteria: Patients in whom tacrolimus trough concentrations cannot be measured on the morning of day 4 before the fourth dose, or those deemed inappropriate for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
Discrepancy between predicted and observed tacrolimus trough concentrations measured on the morning of day 4 before the fourth dose.	—

Countries

Japan

Contacts

Public ContactJunko Horiuchi

Shonan Kamakura General Hospital, Tokushukai Medical Corporation General Affairs Department

j_horiuchi@shonankamakura.or.jp0467-46-1717

Outcome results